# Arbutus Biopharma Corporation (ABUS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.15, market value $1.0 billion.

## Valuation
- **P/E (trailing): 6.5×**. Arbutus Biopharma Corporation trades at 6.5× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 5.6×**. Each dollar of revenue is priced at 5.6×.
- **Price / book: 3.9×**. The shares trade at 3.9× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 15.3%**. The inverse of the P/E: 15.3% of the price is earned each year.

## Profitability
- **Operating margin: 82.0%**. 82.0% of revenue is left after running the business, an exceptional level.
- **Net margin: -237.9%**. The company reported a net loss over the last twelve months.
- **Return on equity: -43.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 201.0%**. Return on all capital, debt included, is 201.0%: comfortably above what that capital costs.
- **Return on assets: 161.8%**. Each dollar of assets produces 161.8% of profit.

## Growth
- **Revenue growth (1 yr): 128.2%** (3-yr -28.8%/yr, 5-yr 15.3%/yr). Revenue grew 128.2% over the last year, against 15.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 55.3%**. Earnings per share rose 55.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Altman Z-score: 33.88**. A Z-score of 33.88 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Arbutus Biopharma Corporation does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 28.4%** (YTD 7.1%, 3-mo 21.2%). The shares are up 28.4% over twelve months including dividends.
- **From 52-week high: -5.5%** (47.1% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 63**. An RSI of 63 is neutral.
- **Beta (1 yr): 1.22** (volatility 48%). Beta of 1.22 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ABUS · Page: https://foliofundamentals.com/stocks/abus

Not investment advice.